Literature DB >> 22687050

Renal aspects of thalassaemia a changing paradigm.

Sunil Bhandari1, Renzo Galanello.   

Abstract

Beta-thalassaemia is characterised by progressive anaemia necessitating regular blood transfusions to sustain life. With the advent of effective chelating agents that can reduce the iron burden and extend patients' survival, renal disease, as in other ageing populations, has become more prevalent. In recent years, chronic kidney disease (CKD) has become overwhelming; indeed, approximately 8% or 6 million people of the UK population has evidence of CKD. Several factors, which occur in patients with thalassaemia, account for the relative explosion of renal disease in the general population including increasing age, diabetes, hypertension and the advent of novel measures of renal function facilitating early detection of kidney disease. In addition, some patients with thalassaemia develop renal tubular dysfunction related to the disease itself, the effects of iron overload and the effects of chelator therapy, while other patients have an increased creatinine clearance leading to hyperfiltration. More recently, there is a noticeable increasing prevalence of impaired renal function and proteinuria because of several putative factors including chelators. We review current data on the potential mechanisms leading to renal abnormalities seen in patients with thalassaemia, the potential effects of iron loading within the kidney and the potential renal effects of chelator therapy. This article gives a speculative account of possible mechanisms and theories to consider providing pause for thought and direct future research in this area.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22687050     DOI: 10.1111/j.1600-0609.2012.01819.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  10 in total

1.  Prevention of renal dysfunction by nutraceuticals prepared from oil rich plant foods.

Authors:  Sahar Y Al-Okbi; Doha A Mohamed; Thanaa E Hamed; Reham Sh Esmail; Souria M Donya
Journal:  Asian Pac J Trop Biomed       Date:  2014-08

Review 2.  Renal complications of beta-thalassemia major in children.

Authors:  Ashraf Bakr; Youssef Al-Tonbary; Ghada Osman; Rasha El-Ashry
Journal:  Am J Blood Res       Date:  2014-09-05

3.  Early Predictors of Renal Dysfunction in Egyptian Patients with β-Thalassemia Major and Intermedia.

Authors:  Azza A G Tantawy; Nagham El Bablawy; Amira A M Adly; Fatma S E Ebeid
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-09-01       Impact factor: 2.576

Review 4.  Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions.

Authors:  Anna W Chalmers; Jamile M Shammo
Journal:  Ther Clin Risk Manag       Date:  2016-02-15       Impact factor: 2.423

5.  Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.

Authors:  Caroline Fradette; Vincent Pichette; Éric Sicard; Anne Stilman; Shalini Jayashankar; Yu Chung Tsang; Michael Spino; Fernando Tricta
Journal:  Br J Clin Pharmacol       Date:  2016-07-18       Impact factor: 4.335

6.  Iron uptake by ZIP8 and ZIP14 in human proximal tubular epithelial cells.

Authors:  S E G van Raaij; S K S Srai; D W Swinkels; R P L van Swelm
Journal:  Biometals       Date:  2019-02-26       Impact factor: 2.949

7.  Kidney tubule iron loading in experimental focal segmental glomerulosclerosis.

Authors:  Dorine W Swinkels; Bart Smeets; Rachel P L van Swelm; Sanne Beurskens; Henry Dijkman; Erwin T G Wiegerinck; Rian Roelofs; Frank Thévenod; Johan van der Vlag; Jack F M Wetzels
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.379

8.  Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.

Authors:  Osama Tanous; Yossi Azulay; Raphael Halevy; Tal Dujovny; Neta Swartz; Raul Colodner; Ariel Koren; Carina Levin
Journal:  BMC Nephrol       Date:  2021-12-20       Impact factor: 2.388

9.  Cardiorenal syndrome in thalassemia patients.

Authors:  Sorasak Makmettakul; Adisak Tantiworawit; Arintaya Phrommintikul; Pokpong Piriyakhuntorn; Thanawat Rattanathammethee; Sasinee Hantrakool; Chatree Chai-Adisaksopha; Ekarat Rattarittamrong; Lalita Norasetthada; Kanda Fanhchaksai; Pimlak Charoenkwan; Suree Lekawanvijit
Journal:  BMC Nephrol       Date:  2020-08-03       Impact factor: 2.388

10.  β-Thalassemia minor & renal tubular dysfunction: is there any association?

Authors:  Mohsen Vakili Sadeghi; Maryam Mirghorbani; Roghayeh Akbari
Journal:  BMC Nephrol       Date:  2021-12-07       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.